We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Innovaderma Plc | LSE:IDP | London | Ordinary Share | GB00BT9PTW34 | ORD EUR0.10 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMIDP
RNS Number : 1851U
InnovaDerma PLC
16 January 2017
InnovaDerma PLC
("InnovaDerma", the "Group" or the "Company")
Trading Update
InnovaDerma (LON: IDP), a UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-tanning and skin rejuvenation, today provides its trading update for the six months ended 31 December 2016.
Trading Performance
The Board is pleased to announce that the Group's first half year financial performance has been encouraging and revenues are expected to show growth of just over 80% year-on-year on a constant currency basis to approximately GBP3.0 million (unaudited). The increase in revenue has been driven by the Company's expansion strategy in the UK with the strong performance of Skinny Tan, a premium self-tanner brand that combines a natural tanning active, to tan and reduce the visible appearance of cellulite, which was launched in February 2016 through Superdrug. As set out in the Full Year results, the Group's strategies are to extend the Skinny Tan brand to build customer loyalty, and use a digital direct to consumer strategy to drive sales. Both have contributed positively to revenue growth.
The Group has undertaken significant corporate activity in the first half including listing on the Main Market of the London Stock Exchange, opening up the US market, and the transition of its manufacturing to the UK. One off costs associated with these activities will be absorbed into the first half of the financial year. As previously indicated by the Board in its operational update and entry into the American market on 24 October and 31 October 2016 respectively, it believes that these strategic initiatives will drive top line revenue and earnings from the second half of the Company's financial year.
The Board is pleased with the progress of the Company and looks forward to discussing this further at the time of its interim results expected to be in February.
The Company considers this announcement to contain inside information which is disclosed in accordance with the Market Abuse Regulation.
Further enquiries
InnovaDerma Haris Chaudhry/Joe Bayer +61 (0)3 9111 0071 --------------------------- ----------------------- Sole broker Hybridan LLP Claire Noyce +44 (0)203 764 2341 --------------------------- ----------------------- Cardew Group Shan Shan Willenbrock David Roach Emma Ruttle + 44 (0)20 7930 0777 --------------------------- -----------------------
About InnovaDerma:
InnovaDerma PLC (LSE: IDP) specializes in the research, manufacture and marketing of clinically proven products in hair loss, anti-ageing and beauty sectors. InnovaDerma has presence in the United Kingdom, Australia, New Zealand, Philippines, South Africa, Hong Kong and South Korea.
www.innovaderma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTOKNDQOBKDQDD
(END) Dow Jones Newswires
January 16, 2017 02:00 ET (07:00 GMT)
1 Year Innovaderma Chart |
1 Month Innovaderma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
